Introduction
Systemic autoinflammatory diseases (sAIDs) belong to a heterogeneous group of rare and severe chronic inflammatory disorders. The term Bautoinflammatory diseaseŵ as first coined by McDermott et al. following the discovery of the mutation responsible for the tumornecrosis-factor-receptor-associated periodic syndrome (TRAPS) [1] . In contrast to autoimmune diseases, hightiter autoantibodies and antigen-specific T cells are usually absent in sAIDs. The uncontrolled inflammation is caused by disturbances in innate immune pathways and results in an overwhelming cytokine release. Clinically, patients with sAIDs present with a wide range of symptoms including recurrent fever, fatigue, gastrointestinal, neurologic, musculo-skeletal and dermatologic manifestations. As skin eruptions like urticarial or maculo-papular exanthema are frequent findings in sAIDs, dermatologists and allergists should be aware of these rare diseases and incorporate them in their differential diagnosis [2•]. The majority of disorders start in early childhood and present with considerable quality of life (QoL) impairment [3•, 4]. Long-term complications include growth and mental retardation and irreversible organ damage such as deafness and amyloid-induced renal failure [5] . Within the last decade, a growing number of hereditary monogenic and acquired multifactorial sAIDs have been identified. Among them are many so-called inflammasomopathies with disturbances in IL-1β production and signalling. Since the introduction of very effective anti-cytokinetargeted therapies, the daily life and long-term prognosis of patients with sAIDs have much improved [6••]. However, the awareness of sAIDs is still limited and diagnostic delay of years or even decades may occur [7] . We here give an overview on the diagnosis and recent advances in the management of sAIDs in childhood.
Classification of systemic autoinflammatory diseases
SAIDs can be classified according to the affected signalling pathway or clinical phenotype. For practical reasons, sAIDs are divided into early-onset monogenic disorders associated with a single disease-causing mutation and multifactorial acquired disorders of variable onset and unknown cause. Within others, monogenic sAIDs include the well-known hereditary periodic fever syndromes (HPFs), namely familiar Mediterranean fever (FMF), mevalonate kinase deficiency (MKD), cryopyrin-associated periodic syndrome (CAPS) and TRAPS. Among the multifactorial acquired diseases that manifest during childhood are systemic juvenile idiopathic arthritis (sJIA) and periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome. Notably, disturbances in innate immune pathways and autoinflammatory mechanisms are not restricted to very rare sAIDs but can be found as contributing factors in frequent inflammatory disorders such as Crohn's disease, gout and diabetes mellitus too [8] [9] [10] .
Systemic autoinflammatory diseases with relevance for dermatologists and allergists
Chronic recurrent wheals are among the most frequent clinical symptoms presented to dermatologists and allergists in daily practice. In the vast majority, chronic urticaria can be diagnosed. However, it is important to not miss other rare causes of recurrent wheals such as autoinflammatory diseases [11] .
Cryopyrin-associated periodic syndrome CAPS represents a rare hereditary autosomal disease entity with an estimated frequency of one to three cases per million people [12] . So far, most affected families and sporadic cases have been diagnosed in North America and Western European countries, but case reports from other descents also exist [7] . CAPS is considered a disease spectrum of three clinical subtypes: familial cold autoinflammatory syndrome (FCAS) as the mildest form, followed by the intermediate subtype Muckle-Wells syndrome (MWS) and the most severe form neonatal-onset multisystemic inflammatory disease, also known as chronic infantile neurological, cutaneous and articular (NOMID/CINCA) syndrome. Overlap between the subtypes may occur [13] , and disease severity ranges from mild daily symptoms and few disease attacks in FCAS to continuous inflammation and severe illness with subsequent organ damage in NOMID. Disease onset usually starts in infancy or early childhood but can also be in adolescence [12] . Clinically, CAPS patients present with cold-induced or spontaneous urticarial rash (Fig. 1) . In addition, recurrent fever episodes, malaise, joint (arthralgia, destructive arthropathy) and ocular (conjunctivitis, uveitis) involvement and neurologic (headache, sterile meningitis) manifestations may occur. In FCAS and MWS, cold temperatures are a major disease trigger that induces urticarial rash, fever and other systemic symptoms. Long-term complications include deafness and AA amyloidosis with subsequent renal failure.
The chronic inflammation in CAPS is caused by a gain of function mutation in the gene encoding for nucleotide-binding-like receptor protein 3 (NLRP3) [14, 15] . NLRP3 belongs to a cytoplasmatic multi-protein complex, the inflammasome, that processes pro-interleukin-1β (pro-IL-1β) and pro-IL-18 [16] . As a consequence of the NLRP3 overactivation, IL-1β and IL-18 are massively secreted which results in systemic inflammatory symptoms as mentioned above [17, 18] .
Systemic juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatic disease in children with a prevalence of 16-150 cases per 100,000 inhabitants [19] and comprises a heterogeneous spectrum of chronic inflammatory and autoimmune disorders. Systemic juvenile idiopathic arthritis (sJIA), also known as Still's disease, represents the most severe JIA subtype and accounts for 5-10 % of JIA cases in Europe (up to 50 % in Japan) [20] [21] [22] . The preferred age of onset lies between 1 and 5 years [23] . Clinical symptoms in sJIA are intermittent high-grade fever, arthritis, salmon-coloured maculo-papular or urticarial exanthema, lymphadenopathy, hepatosplenomegaly and serositis [24] . The clinical disease course distinguishes between monophasic presentation with complete resolution of symptoms (ca. 40 %), chronic remittent disease with active and symptom-free episodes (ca. 10 %) and chronic active disease with progressive joint destruction (ca. 50 %) [25] . A feared acute complication in sJIA is macrophage activation syndrome (MAS) that affects around 10 % of patients and goes along with high fever, cytopenia, impaired liver function, coagulopathy and considerable mortality [26] . Long-term complications also include AA amyloidosis [27, 28] .
Although its pathophysiology is mainly unknown, sJIA is considered a multifactorial acquired sAID. In contrast to other JIA subtypes, sJIA patients do not show human leukocyte antigen (HLA) associations or autoantibodies [24] but upregulation of IL-1-related cytokines (IL-1β, IL-6, lL-18) suggesting an inflammasome-mediated pathogenesis [29] [30] [31] [32] .
Diagnosing systemic autoinflammatory diseases in childhood
In children presenting with chronic urticarial or maculo-papular rash and systemic symptoms such as episodic fever, malaise and joint pain of unknown origin, sAIDs should be explored as a rare differential diagnosis. Usually, the diagnosis is established on the basis of combined clinical symptoms, a positive family history (where applicable) and laboratory results [11] . According to the BInternational League of Associations for Rheumatology^(ILAR), a diagnosis of sJIA relies on the clinical criteria high-grade quotidian fever for ≥3 consecutive days over 2 weeks or more, arthritis and at least one of the following symptoms in children G16 years: evanescent rash, generalized lymphadenopathy, hepatosplenomegaly and serositis [33] .
Clinical diagnostic criteria

Family history
In CAPS patients, a positive family history for urticarial rash and systemic symptoms has been reported in around 60 % of cases [3•]. A negative family history suggests spontaneous mutations and is frequently seen in NOMID patients [34] . In contrast, familiar cases in sJIA are unusual.
Laboratory findings
Typically, autoinflammatory patients present with elevated inflammation markers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) during disease attacks of acute inflammation. Also, S100 proteins S100A8/9 and S100A12 have been shown to be sensitive markers of disease activity and may detect even subclinical inflammation in sAIDs [35, 36] . Further non-specific laboratory findings are inflammation-induced anaemia, leukocytosis and thrombocytosis [19] . Histopathology from lesional skin of urticarial autoinflammatory diseases like CAPS and sJIA reveals neutrophil-rich dermal infiltrates [37] [38] [39] .
The diagnosis of CAPS is confirmed by a heterozygous mutation in the NLRP3 gene. Notably, up to 40 % of patients with typical clinical CAPS phenotype are mutation negative suggesting the existence of other yet unknown genetic abnormalities [34] . In a subgroup of mutation-negative patients, genetic mosaicisms were recorded [34, 40] .
For sJIA, a multifactorial acquired disorder, no genetic tests are available. Genetic association studies revealed no abnormalities in genes of known monogenic sAIDs; nevertheless, genetic polymorphisms in pro-and anti-inflammatory cytokine pathways (e.g. IL-1, IL-6, IL-10) have been reported [32, 41] . In addition, serum ferritin levels are found to be highly elevated (up to ten times above upper limit of normal) in most sJIA patients and may serve as diagnostic biomarker discriminating sJIA from CAPS and other chronic inflammatory disorders [42••] .
Differential diagnosis
Clinical symptoms such as urticarial rash, fever and joint pain are not only observed in CAPS and sJIA but may also occur in many other disorders during childhood. Depending on the leading clinical symptoms, dermatologic, hematologic, infectious, autoimmune and other autoinflammatory conditions have to be excluded (Table 1) .
Management of systemic autoinflammatory diseases
SAIDs are severe chronic inflammatory diseases that may persist for life and/or lead to irreversible long-term complications such as amyloidosis, destructive arthropathy and deafness. Also, sAIDs are associated with considerable mortality due to acute MAS or amyloid-induced renal failure. In order to improve clinical symptoms and QoL, to prevent long-term complications and to inhibit damage progression, the treatment of sAIDs should focus on controlling the aberrant inflammation. 
Pharmacologic treatment options in CAPS
Before the availability of anti-cytokine-targeted therapies, treatment in CAPS was limited to poorly effective corticosteroids, non-steroidal antiphlogistics and immunomodulating drugs. The first evidence of high efficacy of anti-IL-1-targeted drugs in CAPS derived from a case report of two MWS patients with amyloidosis who showed rapid clinical and inflammatory response within hours following the administration of the IL-1 receptor antagonist anakinra [43] . To date, three different anti-IL-1 blockers are available for the use in CAPS: the recombinant IL-1-receptor (IL-1-R) antagonist anakinra (Kineret®), the fusion protein rilonacept (Arcalyst®) consisting of the extracellular fraction of the IL-1-R and an IL-1-R accessory protein and the fully human monoclonal IL-1β antibody, named canakinumab (Ilaris®) ( Table 2 ). All three anti-IL-1 blockers are administered by subcutaneous injections in daily (anakinra), weekly (rilonacept) or 8-weekly (canakinumab) intervals depending on their individual half-life. Placebocontrolled studies with anakinra, rilonacept and canakinumab in children and adults of all CAPS phenotypes demonstrated complete clinical and laboratory response in the majority of patients and led to EMA and FDA approval for this indication [44] [45] [46] . Anti-IL-1 blockade also showed to improve long-term complications such as progressive hearing loss and amyloidosis in MWS and NOMID patients [47] [48] [49] .
Common side effects of anti-IL-1 treatment in CAPS include painful injection site reactions (in particular seen with anakinra), respiratory tract infections and vertigo [44, 45] . Also, a transient increase in transaminases, elevated cholesterol levels and neutropenia may occur [50] . Based on its good efficacy and favourable safety profile, anti-IL-1 blockade is the treatment of choice in symptomatic CAPS patients. [52, 53] . To date, only canakinumab (4-weekly dosing intervals in sJIA) and anti-IL-6 receptor antagonist tocilizumab are approved by EMA and FDA [52, 53] . Tocilizumab (Actemra®, RoActemra®) is a humanized anti-IL-6 receptor antibody that binds to soluble and membrane-bound IL-6 receptor and is administered in 2-weekly intervals i.v. (Table 2 ). Anakinra and rilonacept were effective too in small patient numbers with sJIA [54, 55] . Of note, results from two clinical studies suggested a beneficial effect of early anakinra treatment on the clinical course of sJIA (monophasic vs. chronic intermittent or active disease) as 75-85 % of patients showed inactive disease after 1 year [32, 54] . The adverse events recorded with canakinumab and other anti-IL-1 blockers in sJIA are in line with those reported from CAPS [53] . Side effects of tocilizumab treatment in sJIA patients include increased susceptibility to infections, neutropenia, thrombopenia, hyperlipidemia and elevated transaminases [52] .
Compared to CAPS, sJIA is a more heterogeneous disease. Anti-IL-1 and anti-IL-6 targeting therapies are effective in sJIA, but do not present the overwhelming complete response rates that are known from anti-IL-1 treatment in CAPS. Also, many sJIA patients treated with biologics require additional corticosteroids and/or DMARDs to achieve symptom control. Whether or not anti-cytokine therapies can prevent chronic active disease courses with progressive joint destruction and replace corticosteroids as first-line treatment is still unclear and will be subject of future studies. If the initial corticosteroid therapy does not result in adequate clinical response, the early use of canakinumab or tocilizumab is highly recommended to avoid severe disease-associated complications [51] .
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